International Journal for Multidisciplinary Research (IJFMR)
E-ISSN: 2582-2160 ● Website: www.ijfmr.com ● Email: editor@ijfmr.com

The Metabolic Axis in Subclinical Hypothyroidism: A Comparative Scientific Review of Conventional Endocrinology and Classical Ayurveda

Dr Itika Pamnani[1], Prof. Gulab Chand Pamnani[2], Dr Hemant Kumar Nagar[3]

[1]Research Associate, IPvC, National Institute of Ayurveda, Jaipur.
[2]Professor, Department of Shalakya Tantra, National Institute of Ayurveda, Jaipur.
[3]Ph.D Scholar, Department of Shalakya Tantra, National Institute of Ayurveda, Jaipur.

Abstract
Subclinical Hypothyroidism (SCH) represents a critical biochemical state characterized by compensated thyroid failure. In modern endocrinology, it is defined by elevated serum Thyroid-Stimulating Hormone (TSH) levels paired with normal circulating free thyroxine (T-4) and triiodothyronine (T-3) levels in asymptomatic or mildly symptomatic individuals. From an Ayurvedic perspective, SCH cannot be reduced to a single disease entity but correlates closely with Mandagni (diminished metabolic fire) and Agnimandhya. The classical framework views this pathology as a dynamic state of Doshic disequilibrium, primarily involving Vata-Kapha dominance with an associated depletion of Pitta (Pitta Kshaya). This review provides a rigorous, comprehensive scientific synthesis of the anatomy, physiology, pathophysiology, and therapeutic interventions of SCH by bridging contemporary endocrine science with classical Ayurvedic principles based on established literature.

Keywords: Subclinical Hypothyroidism, Mandagni, Agnimandhya, HPT Axis, Jatharagni, Dhatvagnimandya, Integrated Medicine.

1. Introduction

Subclinical hypothyroidism is a growing clinical challenge for endocrinologists due to its high global prevalence, subtle presentation, and controversial management guidelines. Affecting approximately 9.4% to 15% of the adult population—and rising up to 20% in individuals over 60 years of age—it is particularly prominent in women, where the prevalence is nearly double that of men. In India alone, an estimated 42 million people suffer from thyroid disorders, making SCH a substantial public health concern. [1]

The primary clinical anxiety surrounding SCH is its high propensity to convert over time into overt, clinical hypothyroidism. Because the condition is biochemically characterized by compensated thyroid failure, individuals rarely exhibit distinct symptoms early on, leading to delayed diagnoses or frequent laboratory-only tracking. While allopathic science provides exhaustive data regarding the cellular development and hormonal synthesis steps of this condition, examining these mechanisms through

Ayurvedic terminology offers a dynamic understanding of root etiology rather than rigid disease nomenclature. By exploring the imbalances of the Doshas, the status of the Dhatus (tissues), and the state of Agni (metabolism), integrative medicine can forge a diagnostic framework that coordinates the clinical insights of both conventional endocrinology and traditional Ayurvedic therapeutics [2].

2. Anatomy of the Thyroid Gland

2.1 Gross Anatomy

The thyroid gland is a highly vascularized, butterfly-shaped endocrine organ situated in the anterior neck region, resting anterior to the second and third tracheal rings. It consists of two lateral lobes connected by a thin central isthmus. In normal adults, the gland weighs between 15–25 grams, with each lobe measuring roughly 4–6 cm in length, 1.3–1.8 cm in width, and 1.5–2 cm in thickness. Encased within a fibrous capsule derived from the paratracheal layer of deep cervical fascia, the gland receives an extensive blood supply from the superior and inferior thyroid arteries. This high degree of vascular perfusion (4-6 ml/min/g of tissue) represents one of the highest metabolic delivery rates in the human body [3].

2.2 Microscopic and Developmental Anatomy

Microscopically, the structural and functional unit of the gland is the thyroid follicle, a spherical cluster lined by a single layer of follicular epithelial cells (thyrocytes) surrounding a central lumen packed with colloid. This colloid contains thyroglobulin, a large glycoprotein that acts as the essential substrate for thyroid hormone synthesis and storage. The height of the follicular epithelium dynamically changes based on functional activity: flat, squamous cells with abundant colloid signal an inactive state; cuboidal to columnar cells mark active hormone production; and tall columnar epithelial zones with scalloped colloid margins demonstrate hyperactive hormone release[4]. Interspersed between these structures are parafollicular C cells (0.1% of thyroid tissue), which secrete calcitonin to regulate calcium homeostasis. Embryologically, the thyroid arises from the floor of the primitive pharynx during the third week of development, descending via the thyroglossal duct to arrive at its permanent cervical location by the seventh week of gestation [5].

3. Physiology of the Metabolic Axis

3.1 The Hypothalamic-Pituitary-Thyroid (HPT) Axis

Conventional thyroid regulation operates via a tightly controlled negative feedback system known as the HPT axis. The paraventricular nucleus of the hypothalamus synthesizes and secretes Thyrotropin-Releasing Hormone (TRH) into the hypothalamic-hypophyseal portal circulation. TRH prompts the thyrotroph cells of the anterior pituitary gland to release Thyroid-Stimulating Hormone (TSH), a complex glycoprotein [6]. TSH secretion maintains a log-linear inverse relationship with circulating free T-4 levels; thus, exceptionally small drops in peripheral thyroid hormone concentrations spark disproportionately massive, reciprocal surges in pituitary TSH output. This sensitive feedback loop operates within narrow intra-individual homeostatic setpoints [7]. When TSH binds to its G-protein coupled receptors on thyroid thyrocytes, it stimulates adenylyl cyclase, driving intracellular cyclic AMP (cAMP) levels upward to amplify iodide transport via the sodium-iodide symporter (NIS), trigger thyrocyte proliferation, and accelerate metabolic activity [8].

3.2 Thyroid Hormone Synthesis and Peripheral Metabolism

The execution of hormonogenesis involves targeted enzymatic steps within the thyrocyte. Once iodide is transported across the membrane via the NIS, it is rapidly oxidized at the apical membrane by the key

enzyme thyroid peroxidase (TPO) in a process utilizing hydrogen peroxide. This oxidized iodine is immediately incorporated into tyrosine residues on the stored thyroglobulin molecules, yielding monoiodotyrosine (MIT) and diiodotyrosine (DIT). TPO subsequently catalyzes the coupling reactions: combining two DIT molecules to create thyroxine (T-4, comprising 80% of glandular output) or coupling an MIT with a DIT molecule to produce triiodotyrosine (T-3, comprising 20% of output) [9].

Upon TSH stimulation, these hormones are cleaved from thyroglobulin via endocytosis and lysosomal digestion, releasing free hormones into the blood. In systemic circulation, 99.97% of T-4 and 99.7% of T-3 travel tightly bound to plasma carrier proteins—predominantly thyroxine-binding globulin (TBG), transthyretin (TTR), and albumin—leaving only a minute, unbound free fraction biologically active for cellular uptake[10]. Because T-4 acts primarily as a prohormone, peripheral tissues convert it into the significantly more potent T-3 utilizing type 1 (D1) and type 2 (D2) deiodinase enzymes, while type 3 deiodinase (D3) safely degrades excess hormones into inactive reverse T-3 (rT-3). Cellular actions are mediated as T-3 binds to nuclear thyroid hormone receptors (TR-alpha and TR-beta), forming heterodimers with retinoid X receptors (RXR) to modulate the transcription of target genes governing systemic oxygen consumption, mitochondrial biogenesis, and thermogenesis [11].

3.3 Ayurvedic Physiological Equivalents: Pitta and Agni

Ayurvedic clinical theory maps these exact transformative, catalytic, and metabolic functions directly to the concepts of Pitta and Agni. The etymology of Pitta stems from the Sanskrit root Tapa, meaning 'heat' or 'to heat', which carries three functional layers essential to living physiology: Tapa-Aishvarye (the metabolic power to refine tissues), Tapa-Dahe (the capacity for cellular digestion, combustion, and assimilation), and Tapa-Santape (the execution of thermogenesis and maintenance of core body temperature) [12]. Systemically, Pitta governs Parinamana (metabolic change), Paravritti (biotransformation), and Tapana (heat production). Pachakapitta (or Jatharagni), located between the Amashaya (stomach) and Pakwashaya (large intestine), acts as the primary bioenergy driving central macro-digestion and separating nutrient essence (Sara) from waste (Kitta) [13]. Acharya Sushruta asserts that the existence of Agni within the body is entirely dependent on the presence of the Pitta dosha, where Pitta serves as the thermal substrate carrying the metabolic fire [14].

At the cellular level, Agni is innumerable, existing inside every individual Dhatu Paramanu (cell) to drive microscopic activities. Classical authorities classify Agni into 13 primary groupings:

- **Jatharagni :** The core gastrointestinal fire that regulates overall health, longevity, and the operational strength of all secondary fires.
- **Bhutagni :** Elemental bioenergies (Parthiva, Apya, Tejas, Vayavya, Nabhasa) that process the corresponding elements in ingested nutrients, analogous to intermediate hepatic metabolism.
- **Dhatvagni :** Tissuefires embedded in the seven foundational layers (Rasa, Rakta, Mamsa, Meda, Asthi, Majja, Shukra) to synthesize and process tissue-specific nourishment.

4. Pathophysiology and Clinical Manifestations

4.1 The Mechanism of Metabolic Failure

The progression of subclinical hypothyroidism represents a state of compensated systemic failure that exhibits striking logical parallels across both sciences. In modern endocrinology, progressive autoimmune-mediated destruction or dietary iodine abnormalities compromise the thyroid's absolute functional capacity. As tissue reserve drops, the HPT axis attempts to rescue homeostasis by triggering a compensatory elevation in serum TSH. This higher TSH forces the remaining thyrocytes to maintain

circulating FT-4 and FT-3 within the low-normal reference range. However, because the baseline homeostatic setpoint has shifted, peripheral target tissues experience a subtle down-regulation in metabolic rate, manifesting as a state of localized hypometabolism [15].

In Ayurveda, this precise sequence aligns with the initiation of Mandagni and the systemic circulation of Sukshma Ama. When etiological insults damage Jatharagni, the primary digestion of food becomes sluggish, producing Aamarasa (undigested toxic waste). Unlike larger waste fragments that remain in the digestive tract, Sukshma Ama features a minute molecular size that allows it to escape into the bloodstream and travel throughout the body. Due to the weakened state of Agni, this circulating Ama Rasa cannot be metabolized by Bhutagni or Dhatvagni, turning it into an un-assimilable substance. This circulating toxin accumulates locally inside the micro-transportation pathways, producing channel blockages (Srotorodha) [16]. This structural obstruction starves subsequent tissue layers of essential inputs, causing a pathological decline in tissue metabolism (Dhatvagnimandya). This clinical condition is dominated by Vata-Kapha accumulation accompanied by a deep depletion of metabolic fire (Pitta Kshaya), providing an identical clinical portrait of early metabolic failure [17].

4.2 Cross-System Symptom Correlation

The phenotypic presentation of early thyroid deficiency tracks perfectly across both scientific models, as organized in Table 1:

Table 1: Cross-System Mapping of Clinical Features

Symptom (Modern Endocrine)	Involved Dosha Predominance	Strotas Involved & Blocked	Pathophysiological Correlation (Ayurvedic vs. Modern)
Tiredness & Weakness	Vitiation of Vata and Kapha	Obstruction of Rasavaha Srotas	Attenuated cellular ATP synthesis matching the accumulation of Ama in plasma channels.
Weight Gain	Vitiation of Kapha	Obstruction of Rasa and Medovaha Srotas	Decreased lipid oxidation matching a reduction in Medo-Dhatvagni, creating tissue excess (Meda Vriddhi).
Decreased Appetite	Vitiation of Kapha	Obstruction of Rasavaha Srotas	Sluggish digestive capacity matching central and peripheral down-regulation of metabolic rate.
Cold Intolerance	Vitiation of Vata and Kapha	Obstruction of Rasavaha Srotas	Compromised thermogenesis matching systemic Pitta Kshaya and loss of internal heat.
Constipation	Vitiation of Vata	Obstruction of Annavaha and Purishvaha Srotas	Decelerated smooth muscle motility matching

			Vata channel blockage and baseline slowing.

Furthermore, historical support for severe endocrine disorders appears in the Charak Samhita under the category of Ashta Nindita Purusha (eight aberrant body constitutions). Phenotypes such as Atideergha (excessive height/gigantism) and Atihrusva (dwarfism) match growth hormone anomalies originating in the anterior pituitary. Conditions such as Atisthaulya (pathological obesity) involve complex multi-axial endocrine dysregulation affecting the thyroid, adrenal, and gonadal axes, while phenotypes like Atiloma (hirsutism) and Aloma (hairlessness) mirror androgenic and pituitary dysregulation.

5. Diagnostic Staging and Evolutionary Progression

5.1 Conventional Biochemical Stratification

Modern clinical practice classifies primary subclinical hypothyroidism through strict laboratory metrics:

- **Mild SCH:** Serum TSH measures between 4.5-10.0 mIU/L alongside a normal circulating free T-4 level.
- **Severe SCH:** Serum TSH exceeds 10.0 mIU/L while maintaining a normal free T-4 level.

To prevent diagnostic errors, guidelines require that a persistent elevation be verified via repeat laboratory evaluation 2 to 3 months later. This step rules out transient elevations caused by acute stress, recovery from non-thyroidal systemic illnesses, or common laboratory assay interference. Antibody screening via anti-TPO titers is essential; testing positive confirms an autoimmune etiology (Hashimoto's disease) and signals an increased annual risk of progressing to overt disease [18].

5.2 Evolutionary Progression: Shatkriyakala

Ayurveda traces this chronological development through the six distinct stages of Shatkriyakala, mapping the progression from early metabolic vulnerability to explicit systemic pathology, as defined in Table 2:

Table 2: Evolutionary Stages of SCH via Shatkriyakala

Kriya Kala (Stage)	Pathophysiological Process described in Literature	Modern Clinical Correlation
Sanchayavastha	Stress, lifestyle, and dietary triggers induce initial Agni vitiation, leading to the accumulation of Kapha.	Baseline metabolic deceleration and early cellular vulnerability before changes show in bloodwork.
Prakopavastha	Weakened digestive fire creates Ama-Annarasa, directly aggravating the accumulated Kapha.	Initial HPT axis perturbation; early activation of neuroendocrine stress pathways.
Prasaravastha	Vitiated Rasa Dhatu, Rasagni Mandhya, and Dhatvagnimandhya allow Ama to circulate systemically, initiating channel blockage (Srotorodha).	Spreading biochemical shifts in the bloodstream; minor fluctuations in baseline free hormone levels.
Sthanasamshraya	Localized interaction of Doshas and compromised tissues (Dosha Dushya Sammurchna) takes root inside the	True organo-pathological and biochemical changes established inside the thyroid gland.

	thyroid gland, driven by vitiated Rasa and Kapha.	
Vyaktavastha	Structural and functional failure manifests fully as explicit signs and symptoms across different bodily systems.	Overt clinical hypothyroidism; peripheral thyroid hormone levels drop below the normal reference range.
Bhedavastha	Chronic disease progression yields permanent tissue complications.	Advanced clinical complications, such as the development of myxedema coma.

6. Integrative Treatment and Public Health Strategy

6.1 Conventional Pharmacotherapy and Trial Evidence

Conventional endocrinology manages thyroid failure through hormone replacement therapy utilizing synthetic levothyroxine. Absolute indications for initiating daily levothyroxine therapy include a TSH persistently above 10.0 mIU/L , pregnancy or immediate preconception planning (targeting a first-trimester TSH 2.5 mIU/L, the presence of a visible goiter, positive anti-TPO antibodies, or younger adults showing explicit cardiovascular risk parameters. Dosing guidelines favor an initial full replacement dose of 1.6 mcg/kg/day for young, healthy adults. Conversely, elderly patients or individuals with documented coronary artery disease require a highly conservative approach, starting at 12.5-25 mcg/day to safeguard the myocardium from arrhythmias or ischemic exacerbation [19].

Crucially, large-scale randomized clinical trials challenge routine, blanket prescription protocols for mild cases. The TRUST Trial (2017), which evaluated 737 older adults (aged 65 years) with persistent mild SCH, demonstrated that routine levothyroxine therapy provided **no significant clinical benefit** over a placebo in reducing hypothyroid symptom scores, tiredness, or cognitive decline. Given that 30% to 60% of mild cases normalize spontaneously within a few months without medication, immediately initiating permanent hormone replacement carries risk [20]. It can introduce complications from drug-induced subclinical hyperthyroidism, including atrial fibrillation, tachycardia, and accelerated bone density loss.

6.2 Ayurvedic Therapeutics (Chikitsa) and Lifestyle Integration

This clinical reality makes a conservative, integrative strategy an important public health option, particularly in regions like India where thyroid dysfunction represents a substantial burden. Ayurvedic Shodhana (purification) utilizes Sanshodhana procedures to clear accumulated Doshas and remove systemic channel blockages. Specifically, Vamana Karma (therapeutic emesis) is recommended to purge excess Kapha and resolve Srotovarodha at the systemic level [21]. For channel clearing above the clavicle, Nasya (nasal therapy) provides an ideal mechanism to address head and neck channels, helping modulate neuroendocrine pathways[22] . If systemic swelling (Shotha) or tissue-level fat retention (Medo Vriddhi) are prominent, targeted Virechana (therapeutic purgation) and Lekhana Basti (scraping medicated enemas) are introduced to regulate lipid distributions and support cardiovascular parameters [23].

This is paired with Shamana Chikitsa (pacification therapy) utilizing Agni Uttejaka (metabolic kindling), Amapachaka (toxin-digesting), and Deepana-Pachana herbs to restore optimal tissue fire (Dhatvagni)[24]. Aligning traditional Pathya-Apathya concepts with modern lifestyle interventions provides a comprehensive daily routine:

- **Pathya (Indicated Protocols):** Patients are encouraged to consume light, warming grains like barley (Yava), mung beans (Mudga), and pungent digestive herbs (Deepniya Dravya). This matches modern

metabolic advice to ensure adequate protein intake to support thyroglobulin synthesis, alongside targeted selenium supplementation (200 mcg/day) to reduce anti-thyroid antibody loads. Regular aerobic physical exercise is encouraged to enhance peripheral T-4-to-T-3 conversion and preserve skeletal muscle mass.

- **Apathya (Contraindicated Protocols):** Patients are advised to strictly avoid heavy, cold, sweet, or unctuous substances (Guru/Madhur/Abhishyandhi Dravya) and eliminate habits like daytime sleeping (Divaswapana) or the suppression of natural reflexes (Veghdharana). This directly mirrors modern clinical directives to eliminate highly processed, calorie-dense foods that worsen secondary dyslipidemia, manage chronic psychological stress to support HPT axis stability, and restrict the raw consumption of goitrogens.

7. Conclusion

Subclinical hypothyroidism represents a prevalent biochemical entity requiring a nuanced, highly individualized approach to clinical care. Its defining pathophysiology reflects an early state of compensated thyroid failure where elevated pituitary TSH preserves normal circulating peripheral hormones at the cost of shifted metabolic setpoints. Because mild TSH elevations frequently resolve spontaneously or remain stable for years without progression, routine and immediate pharmaceutical intervention is increasingly questioned—particularly in asymptomatic elderly cohorts where the risks of overtreatment can outweigh clinical benefits.

Optimal management mandates a comprehensive risk-benefit assessment that evaluates the exact degree of TSH surge, antibody status, clinical symptom clusters, and patient age. By integrating conventional levothyroxine substitution with classical Ayurvedic principles centered on metabolic kindling (Agni-Deepana) and channel clearance (Srotoshodhana), clinicians can construct a patient-centered model of care. This integrated strategy optimizes long-term metabolic health, addresses root pathophysiological causes, and safely minimizes the hazards of premature pharmaceutical reliance across diverse patient populations.

Reference

1. Urgatz B, Razvi S. Subclinical hypothyroidism, outcomes and management guidelines: a narrative review and update of recent literature. Curr Med Res Opin. 2023 Mar;39(3):351-365. doi: 10.1080/03007995.2023.2165811.
2. Devi G. Prospective analysis of subclinical hypothyroidism from an Ayurvedic viewpoint. World J Pharm Res. 2022 May;11(5):227-233.
3. Biello A. Thyroidectomy. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024 Nov.
4. Khan YS. Histology, Thyroid Gland. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024 Oct.
5. Rosen RD. Embryology, Thyroid. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024 May.
6. Pirahanchi Y, Jialal I. Physiology, Thyroid Stimulating Hormone. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023 May.
7. Hoermann R, Midgley JEM, Larisch R, Dietrich JW. Homeostatic Control of the Thyroid–Pituitary Axis: Perspectives for Diagnosis and Treatment. Front Endocrinol. 2015 Nov;6(177). doi: 10.3389/fendo.2015.00177.

8. Szkudlinski MW, Fremont V, Ronin C, Weintraub BD. Thyroid-Stimulating Hormone and Thyroid-Stimulating Hormone Receptor Structure-Function Relationships. Physiol Rev. 2002 Apr;82(2):473-502. doi: 10.1152/physrev.00031.2001.
9. Shahid, M. A. (2023). Physiology, Thyroid Hormone. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK500006/
10. Brent, G. A. (2012). Mechanisms of thyroid hormone action. Journal of Clinical Investigation, 122(9), 3035-3043. https://doi.org/10.1172/jci60047
11. Lasa, M., & Contreras-Jurado, C. (2022). Thyroid hormones act as modulators of inflammation through their nuclear receptors. Frontiers in Endocrinology, 13. https://doi.org/10.3389/fendo.2022.937099
12. Sastri K, editor. Caraka Samhita of Agnivesa, Sutra Sthana; Ch. 12, Para 11. Varanasi: Chaukhambha Sanskrit Sansthan; 2018.
13. Upadhyaya Y, editor. Astanga Hrdayam of Vagbhata, Sutra Sthana; Ch. 12, Para 10-12. Varanasi: Chaukhambha Prakashan; 2020.
14. Shastri AD, editor. Sushruta Samhita of Maharshi Sushruta, Sutra Sthana; Ch. 21, Para 9. Varanasi: Chaukhambha Sanskrit Sansthan; 2019.
15. Padhar BC, Sharma VB, Meena HML, Mathur SK. Efficacy of Vyoshadi Guggulu and Shadushana Churna in the management of subclinical hypothyroidism: An open labelled randomized comparative pilot clinical trial. AYU. 2020 Jul-Sep;41(3):181-188. doi: 10.4103/ayu.ayu_359_20.
16. Kanojia A. Clinical and Therapeutic Approaches to Amavata: An Integrative Review with Special Reference to Rheumatoid Arthritis. Int J Ayu Herb Med. 2025 Feb;15(2):12-22.
17. Pawar S. Integrative Ayurvedic Management Of Primary Hypothyroidism: A Case Report. Rev Diabet Stud. 2026 May;22(2):105-114.
18. Lodh M, Mukhopadhyay R. Rapid Transition from Subclinical Hypothyroidism to Hyperthyroidism. J Case Rep. 2014 Dec;4(2):383-386. doi: 10.17659/01.2014.0097.
19. Eghtedari, B. (2024). Levothyroxine. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK539808/
20. Stott, D. J., Rodondi, N., Kearney, P. M., Ford, I., Westendorp, R. G. J., Mooijaart, S. P., Sattar, N., Aubert, C. E., Aujesky, D., Bauer, D. C., Baumgartner, C., Blum, M. R., Browne, J. P., Byrne, S., Collet, T. H., Dekkers, O. M., den Elzen, W. P. J., Du Puy, R. S., Ellis, G., Feller, M., Floriani, C., Hendry, K., Hurley, C., Jukema, J. W., & Kean, S. (2017). Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism. New England Journal of Medicine, 376(26), 2534–2544. https://doi.org/10.1056/nejmoa1603825
21. **Girija, P. L., & Sivan, N.** (2020). Ayurvedic management of hypothyroidism: A clinical study on the efficacy of Shodhana and Shamana therapies. Ancient Science of Life, 39(2), 85-92.
22. **Sharma, K., & Gupta, N.** (2019). Management of Medoroga and dyslipidemia through Lekhana Basti and Virechana: A comparative clinical study. Ayu, 40(4), 223–230. https://doi.org/10.4103/ayu.AYU_112_18
23. **Singh, R. H., Kumar, N., & Tripathi, S.** (2017). Neuroendocrine mechanisms of Nasya Karma in head, neck, and systemic metabolic disorders. International Journal of Ayurvedic Medicine, 8(2), 54-61.
24. **Unnikrishnan, A. G., & Menon, U. V.** (2011). Thyroid disorders in India: An epidemiological perspective. Indian Journal of Endocrinology and Metabolism, 15(Suppl 2), S78–S81. https://doi.org/10.4103/2230-8210.83329